Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial
By Meg Tirrell, CNN
2 minutes ago
wegovy limits 052023
The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart disease-related death by 20% in a major clinical trial in people with cardiovascular disease, the first to show a weight loss drug alone can have such protective effects.
Novo Nordisk studied Wegovy against placebo in addition to standard of care for prevention of major adverse cardiac events in 17,604 adults with heart disease and obesity or who were overweight, but who didn't have diabetes. It called the trial "Select."
The finding of a 20% reduction in heart risk is higher than many experts had anticipated. A similar trial for the type 2 diabetes drug Ozempic, which uses the same ingredient, semaglutide, previously showed it could reduce cardiovascular risk by 26% - but no trial had yet shown a risk reduction in people without diabetes.
"Select is a landmark trial and has demonstrated that semaglutide 2.4mg has the potential to change how obesity is regarded and treated," said Martin Holst Lange, Novo Nordisk's executive vice president for development.
By Meg Tirrell, CNN
2 minutes ago
wegovy limits 052023
The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart disease-related death by 20% in a major clinical trial in people with cardiovascular disease, the first to show a weight loss drug alone can have such protective effects.
Novo Nordisk studied Wegovy against placebo in addition to standard of care for prevention of major adverse cardiac events in 17,604 adults with heart disease and obesity or who were overweight, but who didn't have diabetes. It called the trial "Select."
The finding of a 20% reduction in heart risk is higher than many experts had anticipated. A similar trial for the type 2 diabetes drug Ozempic, which uses the same ingredient, semaglutide, previously showed it could reduce cardiovascular risk by 26% - but no trial had yet shown a risk reduction in people without diabetes.
"Select is a landmark trial and has demonstrated that semaglutide 2.4mg has the potential to change how obesity is regarded and treated," said Martin Holst Lange, Novo Nordisk's executive vice president for development.
Similar Readings (5 items)
Prescription for obesity treatment drug Wegovy begins in Japan
Study: Diabetes, Obesity Drugs Not Linked to Suicidal Thoughts
Don't worry about exercising every day. Working out just 2.5 hours a week gives you many of the same benefits.
Drug Trials Often Do Not Include Overweight People
Walking just once a week may reduce mortality risk, study finds
Summary
Weight loss drug Wegovy showed a 20% reduction in the risk of heart attack, stroke or heart disease-related death in a major clinical trial, "Select," conducted by Novo Nordisk. The trial involved adults with heart disease and obesity or overweight, but without diabetes. This is the first study to